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Aim: As more and more centers has published their treatment results of 
pseudomyxoma peritonei (PMP) with cytoreductive surgery (CRS) and 
hyperthermic intraperitoneal chemotherapy (HIPEC), the data from China 
is missing. Myxoma Department of Aerospace Hospital is the biggest 
center treating PMP in China. The purpose of this study is to report the 
early and long-term outcomes for PMP from this single center. Methods: 
801 appendix-derived PMP out of 1008 consecutive patients treated in 
Myxoma Department of Aerospace Hospital between 2008 and 2019 were 
retrospectively analyzed. Results: Complete cytoreductive surgery (CCRS) 
was achieved in 240 (30%) patients with median PCI of 14(1~39), and 
the rest had maximal tumor debulking (MTD), HIPEC was implemented 
in 96.3% of CCRS and 78.6% of MTD. The major morbidity (grade 
III/IV) was 11.4% and the 30-day operative mortality is 0.7%. The 5- 
and 10-year OS of CCRS was 76.9% and 64.1%, which is significantly 
higher than MTD (5-, 10-year OS as 36.1%, 27.1%; p<0.001). On the 
univariate analysis, all prognostic factors (gender, PSS, interval time, prior 
chemotherapy, prior HIPEC, Peritoneal Cancer Index (PCI), completeness 
of cytoreduction (CC), HIPEC, pathology, present of serous ascites) were 
found to be associated with overall survival except for age. On multivariate 
analysis, only PCI>20, MTD, high pathologic grade and without HIPEC 
were independent factors predicting poorer prognosis. Conclusions: CCRS 
+HIPEC can benefit PMP well with controllable risks. MTD+HIPEC may 
benefit PMP as well when CCRS cannot be achieved after fully asscessment 
by an experienced peritoneal maglignacy center, but the surgery should be 
performed as limited as possible.
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1. Introduction
PMP is an extremely rare clinical condition caused by the widespread implantation of mucinous tumor cells in the abdominal cavity through “redistribution 
phenomenon” described by professor Sugarbaker [1], 
and it usually had a relatively long and slow progressing 
natural course. These relatively inert cells mostly come 
from appendiceal mucinous neoplasms counting about 
87.2%~94% according to previous studies [2-5]. Without 
appropriate treatment, the quality of life and prognosis 
can be really poor among these patients. In early report 
of 44 PMP patients treated by debulking surgery or 
combined with radiation therapy in Mayo Clinic, 35 
died after tracing for 5 years [6]. And the later researches 
reported a 76% and 91% recurrence rate without the 
comprehensive treatment plan of cytoreductive surgery 
(CRS) and hyperthermic intraperitoneal chemotherapy 
(HIPEC) [7,8], and mostly occurred in 2.5 years. As the 
latter combined panel gradually applied in clinical 
treatment, we had already got some achievements. The 
10-year overall survival was as high as 54~70% when 
complete CRS(CCRS) can be achieved according to large 
sample size studies more recently, combined with HIPEC 
undoubtedly [9-12].
Though CRS+HIPEC has become the “gold standard” 
for PMP among almost all peritoneal malignany diagnosis 
and treatment centers, it still not widely recognized by other 
surgeons due to its relatively high mobility and mortality 
and lack of randomized controlled trails (RCT) [13-15]. Cause 
of the rarity of PMP and the long nature course, RCT may 
not be implemented and even for a very long time in the 
future. Thus, a lot high volume center had published their 
research results, but data from China is still missing.
The Myxoma Department of Aerospace Hospital is 
currently the largest PMP diagnosis and treatment center 
in China. More than 1000 PMPs have been treated in 
this center since 2008. Although there are still major 
limitations on knowledge of PMP in China and patients 
with early stage or local metastasis are rarely seen in our 
center, we still wish to share our treatment experience and 
summarize the current situation of PMP in China.
2. Method
2.1 Patients and Preoperative Management
A prospective database of all patients (N=1008) in our 
tertiary care center treated for PMP between Jan 2008 and 
Dec 2019 was retrospectively analyzed. Exclusion criteria 
are as follows: (1) without surgery as the first treatment 
strategy; (2) underwent palliative surgery simply to relieve 
clinical symptoms or accepted “open and close” surgery; 
(3) PMP originated from extra-appendix. The definition 
and pathological classification for PMP are based on the 
PSOGI experts’ consensus in 2016 as follows [16]:
(1) Acellular mucin;
(2) Low-grade mucinous carcinoma peri tonei 
(LGMCP);
(3) High-grade mucinous carcinoma peritonei 
(HGMCP);
(4) High-grade mucinous carcinoma peritonei with 
signet ring cells (HGMCP-S)
The films without accurate classification were re-read 
by pathologist.
Enhanced abdomino-pelvic CT with oral contrast 
angent, serum tumor marker tests (CA19-9, CA125, 
CEA), gastroscopy, colonoscopy, cardiopulmonary 




A midline incision was adopted for all PMP patients. 
At first, the abdominal cavity was fully explored and 
the extent of tumor burden was carefully calculated and 
using Peritoneal Cancer Index (PCI) [17]. Peritonectomy 
combined with visceral resections intending to remove 
all the macroscopic tumors as much as possible was 
processed as Sugarbaker previously described [18,19], 
taking into account its expected morbidity/mortality. The 
completeness of cytoreduction (CC) is as follows: CC-
0: no visible residue; residual tumor: CC-1: <2.5mm; 
CC-2: 2.5mm~2.5cm; CC-3: > 2.5cm when CC-0/1 is 
defined as complete cytoreductive surgery (CCRS) and 
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CC-2/3 as maximal tumor debulking surgery (MTD) with 
unresectable focus [20].
MTD in our department took place in the following 2 
situations:
(1) the small bowel is widely involved with the 
remaining less than 1.5 metres or mesenteric involving 
caused retraction;
(2) tumors invade the serosa of stomach circumference 
or hepatic pedicle.
In the follow-up period for these patients with MTD, 
only if severe clinical symptoms which may seriously 
affected quality of life occurred (such as obstruction, 
fistula et.al), another operation was chosen cautiously. 
2.3 Hyperthermic Intraperitoneal Chemotherapy 
HIPEC was performed after CRS and before digestive 
tract reconstruction with a closed procedure. The 
circulation speed was controlled at 800~1000ml/min, inlet 
temperature was controlled at 43.5°C when the outlet 
was above 41°C during the therapy for 60min. MMC 
30mg/cisplatin 60~80mg was used with a solvent of 
physiological saline. 
3. Data Collection and Analysis
All patients were followed up every 3 to 6 months in the 
first 5 years after surgery with enhanced abdomino-pelvic 
CT and tumor marker evaluation (CEA/CA125/CA19-9) 
in our center, and then annually after 5 years. The outset 
of follow-up was the date of surgery in our hospital, and 
the overall survival (OS) was counted. The follow-up 
period was until Feb, 2019. Perioperative data and follow-
up results were collected statistically after. Post-operative 
complications were graded by Clavien-Dindo criteria, 
with grade III-IV as the major complication and grade V 
as the perioperative death (30-day) [21].
Statistical analysis was performed using SPSS 25.0. 
The t-test was used for the measurement data and Rank 
sum test (Mann-Whitney U test) for those which do not 
meet the normal distribution. The x2- test was used for 
the count data. The overall survival was compared using 
Kaplan-Meier method by log-rank test. The prognostic 
univariate and multivariate analysis were performed using 




From Jan 2008 to Dec 2019, 1008 patients diagnosed 
as PMP were treated in the Myxoma Department of 
Aerospace Hospital. And 801 of them who received 
the comprehensive plan of CRS and HIPEC and 
pathologically confirmed as appendix origin were 
included in this study. 627(78.3%) had received more than 
one surgical procedure before with a median interval time 
of 16 months. 172(21.5%) had previously received HIPEC 
and 246(30.7%) received system chemotherapy without 
CRS. The patient characteristics are shown in Table 1. 
Table 1. characteristics of patient underwent CRS+HIPEC 
with appendix-derived PMP
Variable n(N=801) %
gender male 322 40.20%
female 479 59.80%
age mean(range) 58(17~82)




interval timea ≤12m 336 41.90%
>12m 465 58.10%
Prior 
chemotherpy without 555 69.30%
with 246 30.70%
Prior HIPECb without 629 78.50%
with 172 21.50%
CEA(ng/ml) median(quartile range) 31(6.7~94.2)
CA125(U/ml) median(quartile range) 46.5(22.1~93.9)
CA19-9(U/ml) median(quartile range) 45(10~249)
PCI median(range) 28(1~39)








HIPEC without 129 16.10%
with 672 83.90%










a, the time from diagnosis of PMP to CRS+HIPEC in our department; b, 
previously received HIPEC without CRS.
DOI: https://doi.org/10.30564/jor.v2i2.2272
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CCRS was achieved in 240 (30%) patients dispite a 
median PCI of 14(1~39), of which 30.8% (74/240) were 
20-29 and 5.4% (13/240) were above 30. CC-2 and CC-3 
happened in 237(29.6%) and 324 (40.4%) patients each 
with the median PCI of 27 and 32(p<0.001). HIPEC was 
implemented in 96.3% of CCRS and 78.6% of MTD. 
Except for 42 patients remained unclear pathological 
grade, low-grade PMP is the most common pathological 
type accounting for 66.4% (504/759). CCRS was achieved 
in 27.6% (65/235) and 32.8% (172/352) of patients in 
the HGMCP+/-S group and acellular/LGMCP group, 
respectively, with no significant difference between the 
two groups.
Ascites can be detected in 76.7% and mostly mucious 
or mixed, but serous ascites existed in 31.6%. And we 
found serous ascites associated with the grade of tumors 
(acellular/LGMCP vs HGMCP+/-S: 37.8% vs 55.3%, 
p<0.001). Also, the high-grade+/-S were with significantly 
higher tumor marker levels (median; CEA: 36.4 ng/ml 
vs 28.7ng/ml, p=0.008; CA125: 66.5U/ml vs 38.5 U/
ml, p<0.001;CA19-9: 90.7U/ml vs 36.8U/ml, p<0.001). 
Overall, the mean operation time was 476 min (105~859) 
and the median blood loss is 1500ml (20~11000).
4.2 Morbidity and Mortality
The major morbidity (grade III/IV) was 11.4% (91/801) 
in the entire cohort. Intestinal fistula and anastomotic 
leakage were the most common counting for 44% 
(40/91), followed by post-operative pleural effusion 
(24.2%;22/91) and intra-abdominal bleeding (7.7%;7/91). 
Six patients died within 30 days after surgery, 3 died of 
abdominal infection, 2 died of respiratory failure, and 1 
died of renal failure. The 30-day operative mortality is 
0.7%. Comparing CCRS with MTD, the overall severe 
perioperative complications were slightly higher in MTD 
group (15.7% vs 9.6%, p=0.059).
4.3 Survival Outcomes
Excluding 63(7.9%) patients with inadequate follow-up 
information from the survival analysis, the median follow-
up for the rest is 39 months (1-143). The 3-, 5-and 10-
year overall-survival (OS) was 62.7%, 47%and 37.9% 
for the whole patient population. The 5- and 10-year OS 
was 76.9% and 64.1% when CCRS occurred, which is 
significantly higher than MTD (5-, 10-year OS as 36.1%, 
27.1%; p<0.001). And CC-0 has a much better prognosis 
than CC-1(p<0.01) (Figure 1). The benefit seemed also 
to be found in CC-2 than CC-3(5-year OS 37% vs 30%, 
p=0.034), but the significant difference disappeared when 
adjusted by tumor grade, HIPEC and PCI (p=0.506; 
HR=0.900, 95%CI: 0.659-1.228). 
Figure 1. Overall survival by completeness of 
cytoreduction(CC)
The median OS of MTD combined with or without 
HIPEC was 44 months and 24 months (p<0.001). The 
survival advantage of HIPEC is more pronounced in MTD 
without serous ascites (p<0.001) (Figure 2) compared 
with the opposite (p=0.118) (Figure 3). 
Figure 2. Overall survival by HIPEC for MTD without 
serous ascites
Figure 3. Overall survival by HIPEC for MTD with 
serous ascites
No deaths occurred among the patients diagnosed with 
acellular mucin and significant survival difference can be 
found between each grade (Figure 4). The worst prognosis 
was associated with HGMCP-S with a median OS of 21 
DOI: https://doi.org/10.30564/jor.v2i2.2272
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months. The median OS for LGMCP and HGMCP was 83 
months and 39 months (p<0.001). 
Figure 4. Overall survival by different pathological grades
On the univariate analysis, all prognostic factors were 
found to be associated with OS except for age, as outlined 
in Table 2. On multivariate analysis, PCI≤20, CCRS, 
acellular/LGMCP and HIPEC were independent factors 
predicting a better prognosis (Figure 5).
Table 2. Univariable and multivariable analysis for overall 
survival after CRS+HIPEC
Univariable OS Mutivariable OS















































































Figure 5. Forest plots of cox regression
5. Discussion
AS Sugarbaker proposed the peritonectomy technique 
and the comprehensive treatment model of CRS + HIPEC 
in the 1990s, more and more centers have reported the 
good survival outcomes and prognostic factors of CCRS 
+ HIPEC for PMP, but few centers had treated more than 
500 cases [2,9-12,14,15,22]. Prior to this study, professional team 
of Li Yan from Shijitan hospital has already pubilished 
their results which evaluated the safety of CRS + 
HIPEC in PMP and summarized its clinicopathological 
features [23,24], but still the data from China is lacking. 
Department of Myxoma of the Space Center Hospital is 
currently the largest PMP treatment center in China. This 
article aimed to summarize and share the experience of 
this single center with a large volume.
The 5-year and 10-year survival rates of patients who 
achieved CCRS and MTD in this study were 76.9%, 
64.1%, and 36.1%, 27.1%, the overall major morbidity 
was 11.4%, and the 30-day perioperative mortality was 
0.7 %, Which is similar to previous researches [10-12]. CC 
or HIPEC may be not presented as independent factors 
in several centers [11,12], but the long-term prognosis of 
all CCRSs were excellent and there is no doubt that in 
selected patients to achieve CCRS as much as possible to 
improve the long-term survival with the controllable risks.
However, based on the current situation in China, a 
vast majority of patients have a huge tumor burden in 
the abdominal cavity at the time of consultation, and the 
stomach and small intestine are seriously involved and 
lost the possibility of CCRS. Previous study has reported 
CRS+HIPEC in 100 patients which with PCI≥28 and the 
radical resection rate was 54% [25]. In another research, 
the rate of CCRS even in HGMCP with a median PCI 
DOI: https://doi.org/10.30564/jor.v2i2.2272
6
Journal of Oncology Research | Volume 02 | Issue 02 | July 2020
Distributed under creative commons license 4.0
of 32 can reach 84% [26]. It is undeniable that we have 
a large gap with them. At present, we still have major 
limitations when dealing with tumors involved in hepatic 
pedicle. However, few studies have focused on this part 
of patients with MTD. Considering the relatively higher 
risk than traditional treatment, whether MTD + HIPEC 
should be performed is still ongoing debate [15,27]. Although 
some researchers believe that MTD can still benefit 
PMP in longer OS and improved quality of life, it cannot 
be proved without suitable controls [28,29]. In this study, 
the proportion of MTD is huge. Although the residual 
tumors of CC-2 are significantly smaller and lower 
tumor burden post-operation, we failed to prove CC-2’s 
significant survival advantage over CC-3, consistent with 
the earlier data reported by Sugarbaker [30]. For patients 
who cannot reach CCRS, it seems that expanding the 
scope of surgical resection does not obtain any survival 
benefit. Theoretically, the penetration depth of HIPEC 
cannot cover the residual tumors after MTD and HIPEC 
was not recommended by previous studies. Of the 174 
MTDs reported by Glehen et al., the 5-year OS of patients 
who did not receive HIPEC treatment is only 10%, 
compared to 32%. On multivariate analysis HIPEC was 
an independent factor for OS in MTD in their study [31]. 
Although some studies suggest that the presence of serous 
ascites should be considered for HIPEC [11], the results of 
this study showed that MTD combined with HIPEC can 
still achieve longer survival when PMP without serous 
ascites. More importantly, the Patients with serous ascites 
do not seem to benefit from HIPEC (p = 0.118).
HGMCP+/-S were usually associated with serous 
ascites (55.3%) and significantly higher tumor marker 
levels (CEA, CA125, CA19-9), while acellular / LGMCP 
were usually mucinous. That can be used in preoperative 
and intraoperative judgment. Although there was no 
significant difference in the proportion of CCRS in different 
pathological grades, the prognosis of HGMCP+/-S, 
especially HGMCP-S was much worse than acellular / 
LGMCP. The median survival of HGMCP-S after CRS 
+ HIPEC in this study was only 21 months. C. Mumzo-
Zuluaga [26] reported 65 cases of HGMCP-S with the 
median survival of 2.2 years, though 83% of the cases 
reached CCRS. HGMCP+/-S were independent predictor 
of poorer survival here had been proved previously [11,12,28,32].
PCI is also one of the independent risk factors affecting 
OS, as H. Anderasson and O. Glehen reported [15,33]. The 
worse prognosis of high PCI is considered to be associated 
with lower CCRS probability. Based on the result of a 
multi-center study with the currently largest sample size, 
even in patients with PCI> 30, 10-year OS can still reach 
68% if achieved CCRS [10]. Therefore, for patients with 
high tumor burden, if there is a possibility of complete 
resection after assessment by an experienced center, CRS 
+ HIPEC should be implanted for the optimal prognosis.
Overall, CCRS +HIPEC should always be the primary 
goal for PMPs regardless of PCI and pathology. Once 
CCRS cannot be achieved after fully evaluation in the 
experienced peritoneal maglignacy center, MTD+HIPEC 
should be performed but as limited as possible to 
minimize the surgical trauma. 
Of course, this study has major limitations. First of 
all, as the average rate of CCRS reported by S.Kusamura 
was 84.4% [34], obviously we still have a very long way to 
go. Most of the appendixes were previously removed but 
without clear pathological classification, the pathological 
grades of appendiceal mucinous neoplasm were unknown. 
Also, as a retrospective study, partial data loss (such 
as lymph node metastasis status, recurrence data et al.) 
and case selection bias might be factors affecting the 
results. Whether PMP with limited metastasis just around 
appendix can benefit more or not from CCRS+HIPEC 
cannot be proved in this study. 
Surgery techniques and the understanding of PMP have 
been constantly improving worldwide as time goes, but 
still a lot of things remained unclear. We have treated PMP 
with increasing numbers and the annual volume nearly 
200 in recent years. This article filled the blanks of China 
and we are looking forward for the development in future.
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